TVRD insider transactions
Tvardi Therapeutics Inc. (TVRD) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
TVRD insiders
Everyone who has filed a Form 3, 4, 5 or 144 at Tvardi Therapeutics Inc., latest first. Follow anyone to get their next filing.
- Imran Nizamudin AlibhaiChief Executive Officer, Director, since April 2025
- Kauh John Saewook M.D.Chief Medical Officer, since April 2025
- Stephen Paul O'BrienPrincipal Accounting Officer, since April 2025
- Avi Daniel ConnChief Financial Officer, since April 2025
- Samuel David Tweardy10% owner, since April 2025
- Wallace L Hall JrDirector, since April 2025
- Shaheen WirkDirector, since April 2025
- Susan Ph.D. ShiffDirector
- Yixin ChenVP, Chem, Mfg and Ctrls, since April 2025
- Jeffrey Leroy LarsonSVP, Research & Development, since April 2025
- Cynthia SmithDirector, since April 2025
- Sujal ShahDirector, since April 2025
- Michael S WyzgaDirector, since April 2025
- Christopher PosnerPresident and CEO, Director-$366K
- Scott TerrillionSec'Y; Chief Compliance & G.c.-$339K
- Helen M BoudreauDirector, since August 2023
- Lisa von MoltkeDirector, since November 2022
- Jeffrey L. IvesDirector-$164K
- Martin VogelbaumDirector-$111K
- Joana GoncalvesChief Medical Officer-$640K
- Ryan D MaynardChief Financial Officer, since September 2022-$2,909
- Frederique Ph.D. MenzaghiChief Scientific Off,svp-R&d-$362K
- Csl Ltd10% owner, since August 2022
- Harrison M Bains JrDirector-$65.2K
- Richard MakaraOfficer, since June 2022
- Thomas Charles ReillyOfficer-$51.4K
- Vifor (International) Ltd10% owner, since October 2021
- Derek T ChalmersOfficer, Director-$712K
Recent Form 3, 4, and 5 filings for TVRD
- SEC Form 4 filed by Chief Financial Officer Conn Avi Daniel4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Kauh John Saewook M.D.4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Alibhai Imran Nizamudin4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Conn Avi Daniel4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Kauh John Saewook M.D.4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- SEC Form 4 filed by Principal Accounting Officer O'Brien Stephen Paul4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- Large owner Tweardy Samuel David disposed of 631,316 shares (SEC Form 4)4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- Amendment: Director Hall Wallace L Jr was granted 246,756 shares (SEC Form 4)4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- Amendment: Director Wirk Shaheen was granted 439,194 shares (SEC Form 4)4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
- New insider Tweardy Samuel David claimed ownership of 946,974 shares (SEC Form 3)3 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)